Berlin \/ Hamburg \u2014 YPOG advi\u00adsed lead inves\u00adtor Venrock Health\u00adcare Capi\u00adtal Part\u00adners on the successful Series C finan\u00adcing round of the Martins\u00adried-based biotech company Tubu\u00adlis. The round amounts to EUR 308 million (USD 361 million) and is one of the largest private finan\u00adcing rounds for a Euro\u00adpean biotech company this year. <\/p>\n
In addi\u00adtion to Venrock Health\u00adcare Capi\u00adtal Part\u00adners, other well-known new inves\u00adtors such as Welling\u00adton Manage\u00adment and Ascenta Capi\u00adtal also parti\u00adci\u00adpa\u00adted. Exis\u00adting inves\u00adtors such as Nextech Invest, EQT Life Scien\u00adces, Frazier Life Scien\u00adces, Andera Part\u00adners, Deep Track Capi\u00adtal, Bayern Kapi\u00adtal, Fund+, HTGF, OCCIDENT and Seven\u00adture Part\u00adners also supported the round. <\/p>\n
Tubu\u00adlis<\/strong> is deve\u00adlo\u00adping a pipe\u00adline of novel, indi\u00adca\u00adtion-speci\u00adfic anti\u00adbody drug conju\u00adga\u00adtes (ADCs) that are highly targe\u00adted and tole\u00adra\u00adble thanks to a combi\u00adna\u00adtion of proprie\u00adtary plat\u00adform tech\u00adno\u00adlo\u00adgies and biolo\u00adgi\u00adcal exper\u00adtise. The new funding will prima\u00adrily be used to acce\u00adle\u00adrate the clini\u00adcal deve\u00adlo\u00adp\u00adment of the lead ADC candi\u00addate TUB-040 (for ovarian and lung cancer). TUB-040 is curr\u00adently in a Phase I\/IIa trial and was gran\u00adted fast-track status by the US FDA in June 2024. In addi\u00adtion, the funding will be used to expand Tubu\u00adlis\u2019 pipe\u00adline, inclu\u00adding the clini\u00adcal ADC candi\u00addate TUB-030 (for advan\u00adced solid tumors) and seve\u00adral precli\u00adni\u00adcal programs. The company also plans to expand its tech\u00adno\u00adlogy plat\u00adforms and estab\u00adlish a US subsidiary. <\/p>\n \u201cTubu\u00adlis\u2019 finan\u00adcing round is a strong signal for the inno\u00adva\u00adtive power of the Euro\u00adpean biotech ecosys\u00adtem,\u201d says Dr. Benja\u00admin Ullrich, Co-Mana\u00adging Part\u00adner at YPOG. \u201cWith the support of leading inter\u00adna\u00adtio\u00adnal inves\u00adtors such as Venrock Health\u00adcare Capi\u00adtal Part\u00adners, a company is streng\u00adthe\u00adned that has the poten\u00adtial to signi\u00adfi\u00adcantly change cancer therapy with its novel ADC tech\u00adno\u00adlo\u00adgies. For YPOG, this is another exam\u00adple of our growing role at the inter\u00adsec\u00adtion of life scien\u00adces, deep tech and venture capital.\u201d <\/p>\n Legal advice was provi\u00added in close coope\u00adra\u00adtion with the US law firm Cooley under the leader\u00adship of James Schnei\u00adder, part\u00adner in the Boston office.<\/p>\n Consul\u00adtant Tubu\u00adlis: YPOG<\/strong><\/p>\n Dr. Benja\u00admin Ullrich<\/strong> (Lead, Tran\u00adsac\u00adtions), Part\u00adner, Berlin About Venrock Health\u00adcare Capi\u00adtal Partners<\/strong><\/p>\n Venrock Health\u00adcare Capi\u00adtal Part\u00adners (VHCP) is a health\u00adcare-focu\u00adsed venture capi\u00adtal fund group concen\u00adt\u00adra\u00adting on late-stage invest\u00adments. It invests prima\u00adrily in publicly traded small cap and priva\u00adtely held late stage compa\u00adnies \u2014 parti\u00adcu\u00adlarly in the health\u00adcare and life scien\u00adces sectors, with a special focus on biotech\u00adno\u00adlogy. VHCP focu\u00adses on compa\u00adnies that deve\u00adlop and commer\u00adcia\u00adlize inno\u00adva\u00adtive products and tech\u00adno\u00adlo\u00adgies. Further infor\u00adma\u00adtion can be found at venrock.com. <\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" Berlin \/ Hamburg \u2014 YPOG advi\u00adsed lead inves\u00adtor Venrock Health\u00adcare Capi\u00adtal Part\u00adners on the successful Series C finan\u00adcing round of the Martin\u00ads\u00adried-based biotech company Tubu\u00adlis. The round amounts to EUR 308 million (USD 361 million) and is one of the largest private finan\u00adcing rounds for a Euro\u00adpean biotech company this year. In addi\u00adtion to Venrock Healthcare [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":57094,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[1366],"tags":[],"class_list":["post-57096","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"\n
\nStefan Rich\u00adter (Tax), Part\u00adner, Hamburg
\nDr. Bene\u00addikt Fl\u00f6ter (IP\/IT\/Data Protec\u00adtion), Part\u00adner, Berlin
\nDr. Caro\u00adlin Rasp\u00e9 (Corpo\u00adrate Crime + Compli\u00adance + Inves\u00adti\u00adga\u00adti\u00adons), Part\u00adner, Munich
\nDr. Emma Peters (Tran\u00adsac\u00adtions), Asso\u00adcia\u00adted Part\u00adner, Berlin
\nTobias Lovett (Tran\u00adsac\u00adtions), Asso\u00adcia\u00adted Part\u00adner, Berlin
\nPia Meven (Tran\u00adsac\u00adtions), Asso\u00adcia\u00adted Part\u00adner, Berlin
\nAnna Eick\u00admeier (IP\/IT\/Data Protec\u00adtion), Senior Asso\u00adciate, Berlin
\nThere\u00adsia M.R. Hein\u00adrich (Tran\u00adsac\u00adtions), Senior Asso\u00adciate, Berlin
\nKonstan\u00adtina Natha\u00adnail (IP\/IT\/Data Protec\u00adtion), Asso\u00adciate, Berlin
\nSilke Ricken (Corpo\u00adrate), Asso\u00adciate, Berlin
\nDr. Chris\u00adtian Busmann (Tax), Asso\u00adciate, Hamburg<\/p>\n